ASND

In September 2026, Ascendis Pharma regained exclusive rights to TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S, which led to a decline in shares due to negative sentiment and concerns about independent development costs. Concurrently, the company announced a $400 million share repurchase program to mitigate this negative impact. In August 2026, Ascendis reported strong second-quarter financial results with product revenue more than doubling to €315 million, driven by robust demand for YORVIPATH, SKYTROFA, and the U.S. launch of YUVIWEL, achieving a net profit of €207 million. Also in August 2026, Ascendis and BioMarin Pharmaceutical entered a global settlement and license agreement related to YUVIWEL, providing freedom to operate without patent disputes. In May 2026, the company reported strong first-quarter financial results with total revenue of €247 million, primarily from YORVIPATH, and sold a Rare Pediatric Disease Priority Review Voucher for $187.5 million. In April 2026, Ascendis announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market, replacing its American Depositary Shares, aiming to broaden investor access and enhance liquidity. In February 2026, the FDA granted accelerated approval for once-weekly YUVIWEL for children with achondroplasia.